New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 17, 2014
05:48 EDTINOInovio broadens IP portfolio from UPenn
Inovio Pharmaceuticals has expanded its existing license agreement with the University of Pennsylvania, adding exclusive worldwide rights to technology and intellectual property for novel synthetic therapies against cancer, infectious diseases and new immune activators. Inovio has an ongoing collaborative research agreement with the university to support fundamental research in the area of DNA-based vaccines and immunotherapies. All newly licensed products are in preclinical development. These new pipeline candidates were developed using Inovio's SynCon design approach and were constructed and tested in preclinical animal models for their ability to generate potent antigen-specific T cell and antibody responses. Multiple patents have been filed and several manuscripts are being prepared for peer-reviewed journal publications. Overall, this amendment broadens and strengthens the patent protection around previously licensed oncology and infectious disease targets by in-licensing expanded patents covering candidate products for DNA based synthetic antibodies and those covering dengue fever, H7N9 influenza, additional HPV serotypes as well as certain other undisclosed cancer antigen targets.
News For INO From The Last 14 Days
Check below for free stories on INO the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 23, 2014
16:47 EDTINOInovio files $175M mixed securities shelf
13:21 EDTINOInovio says ITT analysis achieved statistical significance in VGX-3100 trial
Subscribe for More Information
11:21 EDTINOOptions with decreasing implied volatility
Options with decreasing implied volatility: INO SHPG IRBT CMG LXK PSEC CROX ATHN VMW
11:08 EDTINOHigh option volume stocks
Subscribe for More Information
09:44 EDTINOInovio price target raised to $29 from $26 at Piper Jaffray
Subscribe for More Information
09:20 EDTINOInovio's VGX-3100 for cervical dysplasia shows positive Phase II results
Inovio Pharmaceuticals announced successful results from its randomized, double-blind, placebo-controlled phase II trial of VGX-3100 in women with biopsy-proven cervical intraepithelial neoplasia 2/3 associated with human papillomavirus types 16 or 18. Treatment with VGX-3100 resulted in histopathological regression of CIN2/3 to CIN1 or no disease, meeting the study's primary endpoint. The trial demonstrated clearance of HPV in conjunction with regression of cervical lesions. Robust T-cell activity was detected in subjects who received VGX-3100 compared to those who received placebo.
July 21, 2014
07:11 EDTINOInternational Society of DNA Vaccines to hold a conference
Subscribe for More Information
July 11, 2014
11:31 EDTINOOptions with increasing implied volatility
Options with increasing implied volatility: INO AEGR UBNT INVN WTW OREX GNC CREE SD SAN

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use